Bluejay Diagnostics Inc
NASDAQ:BJDX
Intrinsic Value
Bluejay Diagnostics, Inc. operates as a diagnostic company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BJDX.
Bluejay Diagnostics Inc's market capitalization is 1.5m USD.
BJDX stock price is 0.5533 USD.
BJDX.
BJDX. Open DCF Valuation
BJDX. Open Relative Valuation
BJDX.
BJDX's short-term assets (3m USD) exceed its short-term liabilties (2m USD).
BJDX has negative Operating Income for the last twelve months.
BJDX has negative Net Income for the last twelve months.
BJDX's ROE (Return on Equity) for the past 12 months is negative and is equal to -138%.
BJDX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -418%.
BJDX's long-term assets (5m USD) exceed its long-term liabilties (2m USD).
BJDX has negative Free Cash Flow for the last twelve months.
BJDX's D/E (Debt to Equity) is very low and is equal to 0.
BJDX has negative three-year average ROE (Return on Equity): -80%. The company is not efficient at transforming stockholders' equity into net income.
BJDX has negative three-year average ROIC (Return on Invested Capital): -379%. The company is not efficient at using invested capital to generate operating income.
BJDX has negative Net Debt. This means that the company has more cash and short-term investments (2m USD) than debt (12k USD).
BJDX's Altman Z-Score is very low and is equal to -13.93.
BJDX doesn't generate enough operating income (-10m USD) to safely cover interest payments on its debt (1k USD).
Fundamental Analysis
Bluejay Diagnostics Inc
Balance Sheet Decomposition
Bluejay Diagnostics Inc
| Current Assets | 3.2m |
| Cash & Short-Term Investments | 2.2m |
| Other Current Assets | 1m |
| Non-Current Assets | 1.6m |
| PP&E | 1.6m |
| Other Non-Current Assets | 28.7k |
| Current Liabilities | 1.8m |
| Accounts Payable | 491.5k |
| Accrued Liabilities | 1.3m |
| Other Current Liabilities | 4.8k |
| Non-Current Liabilities | 202.3k |
| Long-Term Debt | 12.3k |
| Other Non-Current Liabilities | 190k |
Earnings Waterfall
Bluejay Diagnostics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-10.3m
USD
|
|
Operating Income
|
-10.3m
USD
|
|
Other Expenses
|
357.3k
USD
|
|
Net Income
|
-10m
USD
|
Free Cash Flow Analysis
Bluejay Diagnostics Inc
What is Free Cash Flow?
BJDX Profitability Score
Profitability Due Diligence
Bluejay Diagnostics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Bluejay Diagnostics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
BJDX Solvency Score
Solvency Due Diligence
Bluejay Diagnostics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Bluejay Diagnostics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BJDX Price Targets Summary
Bluejay Diagnostics Inc
Ownership
BJDX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BJDX Price
Bluejay Diagnostics Inc
| Average Annual Return | -65.92% |
| Standard Deviation of Annual Returns | 29.28% |
| Max Drawdown | -99% |
| Market Capitalization | 1.5m USD |
| Shares Outstanding | 2 688 450 |
| Percentage of Shares Shorted | 0.49% |
Company Profile
Bluejay Diagnostics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-11-10. The firm is engaged in the developing and marketing minimally invasive point of care (POC) diagnostics tests and devices that provide patients and providers with access to healthcare. The firm offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. The company focuses on offering solution to the infectious disease, inflammation, and oncology markets. The Company’s ALLEREYE diagnostic test (ALLEREYE) is a POC device that offers healthcare providers a solution for diagnosis of allergic conjunctivitis. The firm's product candidate includes Symphony IL-6 Sepis triage, Symphony IL-6 LDT market, Symphony IL-6 SEPSIS, Symphony hsTNT/I and NT-proBNP. The company is utilizing the platform for detection of sepsis, cancer and other diseases. The company is also developing biomarkers for detection of other diseases, such as cardiac ischemia and congestive heart failure.
You don't have any saved screeners yet
